# The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer

> **NCT03220984** · PHASE2 · UNKNOWN · sponsor: **Gangnam Severance Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Immuncell-LC intravenous infusion using a CIK cell agent

## Key facts

- **NCT ID:** NCT03220984
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-16
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220984, "The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03220984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*